Hikma Pharmaceuticals Confident on 2026 Targets Despite Flat Injectables Sales

Hikma Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Hikma expects to meet its 2026 targets, with strength in MENA branded medicines and prescription drugs offsetting flat injectables sales. Injectables margins are forecast at 27%–28%, partly affected by a regional supplier issue and related penalty.
  • The company is investing in future injectables growth, including ready-to-use products, expanded European capacity and a U.S. commercial team. A major contract-manufacturing deal at its Columbus facility could contribute significantly from 2027 onward.
  • MENA branded medicines remain a strong performer despite geopolitical disruption and higher shipping costs, supported by local manufacturing and a more differentiated portfolio. CEO Said Darwazah expects to remain in the role for about two years while preparing future leadership.
  • Five stocks to consider instead of Hikma Pharmaceuticals.

Hikma Pharmaceuticals LON: HIK expects to meet its 2026 commitments, with strong performance in its Middle East and North Africa branded medicines business and prescription drugs helping offset a flat year for injectables, CEO Said Darwazah said.

Speaking at a Jefferies event, Darwazah said Hikma had narrowed its outlook after raising the lower end of its earnings guidance at nine months. He described 2026 as a transitional year in which the company invested in facilities, hired staff and prepared for future growth.

“Overall, we feel very confident that we have tightened, as we say, the outlook for the year,” Darwazah said. “We are very comfortable that we will achieve what we set out to do at the beginning of the year.”

The CEO said Hikma now expects injectables sales to be flat compared with the previous year, having initially anticipated low-single-digit growth of about 1% to 2%. He put the business’s margins at 27% to 28%, citing supply problems involving a supplier in the MENA region and a related penalty. Excluding MENA injectable sales, margins in the U.S. and European businesses would be close to 30%, he said.

Injectables expansion and contract manufacturing

Hikma sees several opportunities to expand its injectables business, including ready-to-use products, European hospital sales and contract manufacturing, executives said.

Director of Investor Relations Susan Ringdal said the company had made progress building commercial capabilities for TYZAVAN, its ready-to-use vancomycin product, and expected a stronger performance next year. Hikma is also developing a pipeline of differentiated injectables, long-acting products and peptides at its Zagreb research facility, she said.

Darwazah said additional ready-to-use products are expected from 2028 onward, with an increase in activity anticipated in 2028 and 2029. The company is investing in a U.S. commercial team that could support those launches alongside TYZAVAN.

In contract manufacturing, Darwazah said Hikma had signed a major deal with a large pharmaceutical company to produce a product at its Columbus facility. The partner helped fund a tailored facility, he said, and the product could contribute significantly to growth in 2027 and beyond.

Hikma is also upgrading its Bedford facility and preparing to launch a seventh plant in Portugal, Darwazah said. The company has decided to upgrade smaller injectable manufacturing facilities in Germany and Italy rather than close them, as it seeks to address supply constraints in Europe.

Ringdal said Hikma has expanded its European capabilities beyond its historical bases in Germany, Portugal and Italy, and is considering further markets. Acquisition opportunities could potentially accelerate that expansion, she said.

MENA performance and future leadership

Darwazah said Hikma had become the largest pharmaceutical company in MENA and described its branded business there as a strong performer despite geopolitical disruption and higher shipping costs. He said closer relationships with health authorities and local manufacturing have supported the business.

Discussing the branded business’s profitability, Darwazah pointed to a shift toward chronic diseases, a more differentiated product portfolio, more stable currencies and local manufacturing. He also said Hikma had become a major regional supplier of oncology products by volume.

On succession, Darwazah said he would aim to remain CEO for about two years but could stay somewhat longer if needed to prepare the organization and develop its next generation of leaders. Hikma has announced a new chief financial officer, and Ringdal said she is due to join in March.

Darwazah suggested the company might provide a new medium-term outlook by the end of next year, after giving the incoming CFO time to assess the business. Ringdal said Hikma also plans investor events to explain its growth drivers for 2028 and 2029.

About Hikma Pharmaceuticals (LON:HIK)

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Hikma Pharmaceuticals Right Now?

Before you consider Hikma Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.

While Hikma Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines